But the Swiss company can check one potential solution off its list as a phase 3 trial of its high-dose version ... Novartis’ Kesimpta, a monthly subcutaneous shot which can be delivered at ...
“[This new] data adds to the previously presented efficacy data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension that showed continuous treatment with Kesimpta for up ...
Management reiterated plans to begin the Phase 3 trial for larsucosterol if sufficient funding is secured. Brown emphasized that the trial design is streamlined to minimize variability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback